Faecal metabolite deficit, gut inflammation and diet in Parkinson's disease: Integrative analysis indicates inflammatory response syndrome

ABSTRACT Background Gut‐brain axis is widely implicated in the pathophysiology of Parkinson's disease (PD). We take an integrated approach to considering the gut as a target for disease‐modifying intervention, using continuous measurements of disease facets irrespective of diagnostic divide. Methods We characterised 77 participants with diagnosed‐PD, 113 without, by dietary/exogenous substance intake, faecal metabolome, intestinal inflammation, serum cytokines/chemokines, clinical phenotype including colonic transit time. Complete‐linkage hierarchical cluster analysis of metabolites discriminant for PD‐status was performed. Results Longer colonic transit was linked to deficits in faecal short‐chain‐fatty acids outside PD, to a ‘tryptophan‐containing metabolite cluster’ overall. Phenotypic cluster analysis aggregated colonic transit with brady/hypokinesia, tremor, sleep disorder and dysosmia, each individually associated with tryptophan‐cluster deficit. Overall, a faster pulse was associated with deficits in a metabolite cluster including benzoic acid and an imidazole‐ring compound (anti‐fungals) and vitamin B3 (anti‐inflammatory) and with higher serum CCL20 (chemotactic for lymphocytes/dendritic cells towards mucosal epithelium). The faster pulse in PD was irrespective of postural hypotension. The benzoic acid‐cluster deficit was linked to (well‐recognised) lower caffeine and alcohol intakes, tryptophan‐cluster deficit to higher maltose intake. Free‐sugar intake was increased in PD, maltose intake being 63% higher (p = .001). Faecal calprotectin was 44% (95% CI 5%, 98%) greater in PD [p = .001, adjusted for proton‐pump inhibitors (p = .001)], with 16% of PD‐probands exceeding a cut‐point for clinically significant inflammation compatible with inflammatory bowel disease. Higher maltose intake was associated with exceeding this calprotectin cut‐point. Conclusions Emerging picture is of (i) clinical phenotype being described by deficits in microbial metabolites essential to gut health; (ii) intestinal inflammation; (iii) a systemic inflammatory response syndrome.

[1]  Dr. Shefali Chaudhary,et al.  In vitro and in vivo NMR based metabolomics in Parkinson's disease , 2022, Journal of Magnetic Resonance Open.

[2]  V. Fung,et al.  \Association between Microscopic Colitis and Parkinson's Disease in a Swedish Population , 2021, Movement disorders : official journal of the Movement Disorder Society.

[3]  N. Pedersen,et al.  Association Between Microscopic Colitis and Parkinson's Disease in a Swedish Population , 2021, Movement disorders : official journal of the Movement Disorder Society.

[4]  R. Dobbs,et al.  Intestinal inflammation and compromised barrier function in idiopathic parkinsonism: scenario captured by systematic review , 2021 .

[5]  A. Lang,et al.  Gut Microbial Ecosystem in Parkinson Disease: New Clinicobiological Insights from Multi‐Omics , 2020, Annals of neurology.

[6]  L. Atzori,et al.  Gut Microbiota and Metabolome Alterations Associated with Parkinson’s Disease , 2020, mSystems.

[7]  Krishna R. Kalari,et al.  Longitudinal Multi-omics Reveals Subset-Specific Mechanisms Underlying Irritable Bowel Syndrome , 2020, Cell.

[8]  M. Maniati,et al.  Calprotectin in inflammatory bowel disease , 2020, Clinica Chimica Acta.

[9]  F. Scheperjans,et al.  Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson’s disease , 2020, medRxiv.

[10]  R. Dobbs,et al.  Distinctive Pathophysiology Underlying Constipation in Parkinson’s Disease: Implications for Cognitive Inefficiency , 2020, Journal of clinical medicine.

[11]  E. Tolosa,et al.  LRRK2 in Parkinson disease: challenges of clinical trials , 2020, Nature Reviews Neurology.

[12]  B. Baban,et al.  Niacin for Parkinson's disease , 2020 .

[13]  A. Hart,et al.  The gut virome: the ‘missing link’ between gut bacteria and host immunity? , 2019, Therapeutic advances in gastroenterology.

[14]  Kelly A. Mills,et al.  Dopamine transporter availability reflects gastrointestinal dysautonomia in early Parkinson disease. , 2018, Parkinsonism & related disorders.

[15]  T. R. Licht,et al.  Microbial tryptophan catabolites in health and disease , 2018, Nature Communications.

[16]  Praveen Jha,et al.  Optimal cut‐off value of fecal calprotectin for the evaluation of ulcerative colitis: An unsolved issue? , 2018, JGH open : an open access journal of gastroenterology and hepatology.

[17]  C. Franceschi,et al.  Inflammaging: a new immune–metabolic viewpoint for age-related diseases , 2018, Nature Reviews Endocrinology.

[18]  D. P. de Sousa,et al.  Antifungal activity of cinnamic acid and benzoic acid esters against Candida albicans strains , 2018, Natural product research.

[19]  L. Stronati,et al.  NOD2 and inflammation: current insights , 2018, Journal of inflammation research.

[20]  James T. Morton,et al.  Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome , 2017, Movement disorders : official journal of the Movement Disorder Society.

[21]  K. Fassbender,et al.  Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls. , 2016, Parkinsonism & related disorders.

[22]  Y. Loh,et al.  Aberrations in Peripheral Inflammatory Cytokine Levels in Parkinson Disease: A Systematic Review and Meta-analysis. , 2016, JAMA neurology.

[23]  R. Dobbs,et al.  Quantifying rigidity of Parkinson's disease in relation to laxative treatment: a service evaluation , 2016, British journal of clinical pharmacology.

[24]  Elaine Holmes,et al.  Optimized Sample Handling Strategy for Metabolic Profiling of Human Feces. , 2016, Analytical chemistry.

[25]  R. Brüschweiler,et al.  Emerging new strategies for successful metabolite identification in metabolomics. , 2016, Bioanalysis.

[26]  Jingyuan Fu,et al.  Proton pump inhibitors affect the gut microbiome , 2015, Gut.

[27]  A. Lees,et al.  Constipation preceding Parkinson's disease: a systematic review and meta-analysis , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[28]  R. Dobbs,et al.  Peripheral aetiopathogenic drivers and mediators of Parkinson’s disease and co-morbidities: role of gastrointestinal microbiota , 2015, Journal of NeuroVirology.

[29]  C. Ponsioen,et al.  Impact of disease location on fecal calprotectin levels in Crohn’s disease , 2015, Scandinavian Journal of Gastroenterology.

[30]  Wei Wu,et al.  Clinical characteristics and peripheral T cell subsets in Parkinson's disease patients with constipation. , 2015, International journal of clinical and experimental pathology.

[31]  K. Walters,et al.  Prediagnostic presentations of Parkinson's disease in primary care: a case-control study , 2015, The Lancet Neurology.

[32]  Huidong Shi,et al.  Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. , 2014, Immunity.

[33]  G. Cremaschi,et al.  Niacin Modulates Pro-inflammatory Cytokine Secretion. A Potential Mechanism Involved in its Anti-atherosclerotic Effect , 2013, The open cardiovascular medicine journal.

[34]  A. B. Lyons,et al.  CC Chemokine Ligand 20 and Its Cognate Receptor CCR6 in Mucosal T Cell Immunology and Inflammatory Bowel Disease: Odd Couple or Axis of Evil? , 2013, Front. Immunol..

[35]  A. Charlett,et al.  Antimicrobial Surveillance in Idiopathic Parkinsonism: Indication‐Specific Improvement in Hypokinesia Following Helicobacter pylori Eradication and Non‐Specific Effect of Antimicrobials for Other Indications in Worsening Rigidity , 2013, Helicobacter.

[36]  M. Britschgi,et al.  Mind the gut: secretion of α‐synuclein by enteric neurons , 2013, Journal of neurochemistry.

[37]  D. Devos,et al.  Colonic inflammation in Parkinson's disease , 2013, Neurobiology of Disease.

[38]  R. Dobbs,et al.  Leukocyte-subset counts in idiopathic parkinsonism provide clues to a pathogenic pathway involving small intestinal bacterial overgrowth. A surveillance study , 2012, Gut Pathogens.

[39]  K. Shannon,et al.  Is alpha‐synuclein in the colon a biomarker for premotor Parkinson's Disease? Evidence from 3 cases , 2012, Movement disorders : official journal of the Movement Disorder Society.

[40]  D. Douek,et al.  Microbial translocation across the GI tract. , 2012, Annual review of immunology.

[41]  Chuong B. Do,et al.  Comprehensive Research Synopsis and Systematic Meta-Analyses in Parkinson's Disease Genetics: The PDGene Database , 2012, PLoS genetics.

[42]  Timothy S. Blackwell,et al.  Regional Neural Activation Defines a Gateway for Autoreactive T Cells to Cross the Blood-Brain Barrier , 2012, Cell.

[43]  M. Lappas,et al.  The anti-inflammatory and antioxidative effects of nicotinamide, a vitamin B(3) derivative, are elicited by FoxO3 in human gestational tissues: implications for preterm birth. , 2011, The Journal of nutritional biochemistry.

[44]  Masamichi Yokokura,et al.  Neuroinflammation in the living brain of Parkinson's disease. , 2009, Parkinsonism & related disorders.

[45]  M. Onofrj,et al.  Peripheral cytokines profile in Parkinson’s disease , 2009, Brain, Behavior, and Immunity.

[46]  J. Jankovic,et al.  Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results , 2008, Movement disorders : official journal of the Movement Disorder Society.

[47]  Honglei Chen,et al.  Peripheral inflammatory biomarkers and risk of Parkinson's disease. , 2007, American journal of epidemiology.

[48]  Geert Mayer,et al.  The REM sleep behavior disorder screening questionnaire—A new diagnostic instrument , 2007, Movement disorders : official journal of the Movement Disorder Society.

[49]  H. Senn,et al.  Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in 1H NMR metabonomics. , 2006, Analytical chemistry.

[50]  D. Drossman,et al.  The functional gastrointestinal disorders and the Rome III process. , 1999, Gastroenterology.

[51]  G. Halliday,et al.  A possible role for humoral immunity in the pathogenesis of Parkinson's disease. , 2005, Brain : a journal of neurology.

[52]  H. Cartwright,et al.  Application of fast Fourier transform cross-correlation for the alignment of large chromatographic and spectral datasets. , 2005, Analytical chemistry.

[53]  M. Fujimiya,et al.  Short-chain fatty acids stimulate colonic transit via intraluminal 5-HT release in rats. , 2003, American journal of physiology. Regulatory, integrative and comparative physiology.

[54]  I. Baskakov,et al.  The osmophobic effect: natural selection of a thermodynamic force in protein folding. , 2001, Journal of molecular biology.

[55]  R. Dobbs,et al.  Association of circulating TNF‐α and IL‐6 with ageing and parkinsonism , 1999 .

[56]  R. Dobbs,et al.  Cortisol is higher in parkinsonism and associated with gait deficit , 1998, Acta neurologica Scandinavica.

[57]  S. Lewis,et al.  Stool form scale as a useful guide to intestinal transit time. , 1997, Scandinavian journal of gastroenterology.

[58]  D. Pittet,et al.  The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. , 1995, JAMA.

[59]  R. Bone,et al.  The Systemic Inflammatory Response Syndrome (SIRS) , 1995 .

[60]  C. Frith,et al.  Hypothesis: the bradyphrenia of parkinsonism is a nosological entity , 1993, Acta neurologica Scandinavica.

[61]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[62]  A. Beck,et al.  An inventory for measuring clinical anxiety: psychometric properties. , 1988, Journal of consulting and clinical psychology.

[63]  D. Bender,et al.  Niacin depletion in Parkinsonian patients treated with L-dopa, benserazide and carbidopa. , 1979, Clinical science.

[64]  R. Holt.  Topical Pharmacology of Imidazole Antifungals , 1976, Journal of cutaneous pathology.

[65]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[66]  T. Caliński,et al.  A dendrite method for cluster analysis , 1974 .

[67]  A. Beck,et al.  Assessment of depression: the depression inventory. , 1974, Modern problems of pharmacopsychiatry.

[68]  Richard O. Duda,et al.  Pattern classification and scene analysis , 1974, A Wiley-Interscience publication.